Compare Cadila Healthcare with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs GLENMARK PHARMA - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE GLENMARK PHARMA CADILA HEALTHCARE/
GLENMARK PHARMA
 
P/E (TTM) x 28.6 15.1 189.9% View Chart
P/BV x 4.6 2.5 186.2% View Chart
Dividend Yield % 0.7 0.4 184.2%  

Financials

 CADILA HEALTHCARE   GLENMARK PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-20
GLENMARK PHARMA
Mar-19
CADILA HEALTHCARE/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs352712 49.5%   
Low Rs207484 42.7%   
Sales per share (Unadj.) Rs139.2349.6 39.8%  
Earnings per share (Unadj.) Rs11.832.8 35.9%  
Cash flow per share (Unadj.) Rs18.644.3 41.9%  
Dividends per share (Unadj.) Rs3.502.00 175.0%  
Dividend yield (eoy) %1.30.3 374.3%  
Book value per share (Unadj.) Rs101.4198.6 51.0%  
Shares outstanding (eoy) m1,023.74282.17 362.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.01.7 117.4%   
Avg P/E ratio x23.718.2 130.3%  
P/CF ratio (eoy) x15.013.5 111.6%  
Price / Book Value ratio x2.83.0 91.6%  
Dividend payout %29.86.1 487.6%   
Avg Mkt Cap Rs m286,033168,625 169.6%   
No. of employees `00013.412.0 111.4%   
Total wages/salary Rs m24,14520,561 117.4%   
Avg. sales/employee Rs Th10,632.78,196.0 129.7%   
Avg. wages/employee Rs Th1,801.21,708.1 105.4%   
Avg. net profit/employee Rs Th898.5768.5 116.9%   
INCOME DATA
Net Sales Rs m142,53198,655 144.5%  
Other income Rs m1,1392,081 54.7%   
Total revenues Rs m143,670100,736 142.6%   
Gross profit Rs m24,19815,858 152.6%  
Depreciation Rs m6,9653,259 213.7%   
Interest Rs m3,4183,346 102.2%   
Profit before tax Rs m14,95411,335 131.9%   
Minority Interest Rs m2880-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m3,1983,756 85.1%   
Profit after tax Rs m12,0449,250 130.2%  
Gross profit margin %17.016.1 105.6%  
Effective tax rate %21.433.1 64.5%   
Net profit margin %8.59.4 90.1%  
BALANCE SHEET DATA
Current assets Rs m87,15466,968 130.1%   
Current liabilities Rs m82,69440,211 205.7%   
Net working cap to sales %3.127.1 11.5%  
Current ratio x1.11.7 63.3%  
Inventory Days Days7183 85.7%  
Debtors Days Days9481 115.5%  
Net fixed assets Rs m133,23633,322 399.8%   
Share capital Rs m1,024282 362.9%   
"Free" reserves Rs m102,73355,770 184.2%   
Net worth Rs m103,75756,052 185.1%   
Long term debt Rs m32,14635,738 90.0%   
Total assets Rs m236,866132,888 178.2%  
Interest coverage x5.44.4 122.5%   
Debt to equity ratio x0.30.6 48.6%  
Sales to assets ratio x0.60.7 81.1%   
Return on assets %6.59.5 68.9%  
Return on equity %11.616.5 70.3%  
Return on capital %13.717.8 77.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m52,75262,998 83.7%   
Fx outflow Rs m14,50422,859 63.5%   
Net fx Rs m38,24840,140 95.3%   
CASH FLOW
From Operations Rs m25,05413,242 189.2%  
From Investments Rs m-10,123-6,990 144.8%  
From Financial Activity Rs m-10,942-7,387 148.1%  
Net Cashflow Rs m3,989-2,971 -134.3%  

Share Holding

Indian Promoters % 74.8 48.3 154.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 6.9 120.3%  
FIIs % 5.9 34.4 17.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 10.5 104.8%  
Shareholders   44,069 56,727 77.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   STERLING BIOTECH  PFIZER  ALKEM LABORATORIES  ORCHID PHARMA  SANOFI INDIA  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 531 Points; Reliance Industries & IndusInd Bank Fall 5%(Closing)

Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.

Related Views on News

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)

Sep 1, 2020 | Updated on Sep 1, 2020

For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

One Chart to See Before You Sell(Fast Profits Daily)

Jan 22, 2021

In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.

Invest in the Multibaggers of 2021 and Beyond(Profit Hunter)

Jan 21, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Jan 25, 2021 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS